Precigen (PGEN) Times Interest Earned (2012 - 2026)
Precigen (PGEN) posted quarterly Times Interest Earned of -$2.06 for Q1 2026, up 96.21% year-over-year from -$1.05 in Q1 2025, and up 75.2% quarter-over-quarter from -$8.31 in Q4 2025.
Precigen (PGEN) Times Interest Earned (2012 - 2026) Analysis & Trends
Precigen (PGEN) has reported Times Interest Earned for 15 consecutive years, with -$2.06 the latest figure, recorded in Q1 2026.
- In Q1 2026, Times Interest Earned rose 96.21% year-over-year to -$2.06; the TTM figure through Mar 2026 stood at -$10.94 (up 70.07% YoY), while the FY2025 annual figure was -$0.28, up 15.19% from the prior year.
- Times Interest Earned climbed to -$2.06 in Q1 2026 per PGEN's latest filing, from -$8.31 in the prior quarter.
- Across five years, Times Interest Earned topped out at $15.43 in Q4 2022 and bottomed at -$20937.0 in Q3 2023.
- Historically, Times Interest Earned has averaged -$2164.4 across 5 years, with a median of -$11.71 in 2022.
- Annual changes were most pronounced in 2022 — Times Interest Earned surged 920.88% — and 2023, when it plunged 559759.89%.
- Precigen's Times Interest Earned stood at $15.43 in 2022, then sank by 31794.08% to -$4889.1 in 2023, then surged by 99.78% to -$10.74 in 2024, then gained by 22.62% to -$8.31 in 2025, then jumped by 75.2% to -$2.06 in 2026.
- Business Quant data shows PGEN's Times Interest Earned at -$2.06 in Q1 2026, -$8.31 in Q4 2025, and -$0.92 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Precigen | 2.18 Bn | 2.18 Bn | 52.17 Mn | 0.32 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 0.32 |
| Mar 31, 2026 | -2.06 |
| Dec 31, 2025 | -8.31 |
| Sep 30, 2025 | -0.92 |
| Jun 30, 2025 | -25.15 |
| Mar 31, 2025 | -54.32 |
| Dec 31, 2024 | -10.74 |
| Sep 30, 2024 | -10,631.00 |
| Jun 30, 2024 | -7.09 |
| Mar 31, 2024 | -42.67 |
| Dec 31, 2023 | -4,889.14 |
| Sep 30, 2023 | -20,937.00 |
| Jun 30, 2023 | -155.29 |
| Mar 31, 2023 | -25.41 |
| Dec 31, 2022 | 15.43 |
| Sep 30, 2022 | -3.74 |
| Jun 30, 2022 | -11.71 |
| Mar 31, 2022 | -6.27 |
| Dec 31, 2021 | -1.88 |
| Sep 30, 2021 | -4.52 |